Response to Letter to the Editor: “Myonectin Predicts the Development of Type 2 Diabetes”

Li, Kejia; Liao, Xin; Wang, Kuan; Mi, Qiao; Zhang, Tingran; Jia, Yanjun; Xu, Xiaohuei; Luo, Xiaoheu; Zhang, Cheng; Liu, Hua; Wang, Cong-Yi; Li, Ling; Yang, Gangyi

doi:10.1210/jc.2018-01228

Cited by 1 publication

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although myonectin was initially described in 2012, by Seldin et al, as a lipid turnover regulator [ 65 ], the same substance was referred to as an erythroferrone two years later and was said to function as an erythrocyte-derived regulator of iron metabolism, as the inhibitor of hepcidin [ 78 ]. These terms are often used interchangeably in the literature, depending on the main area of interest in the particular study [ 79 ]. Little is known about a link between these two apparently different types of mechanisms.…”

Section: Myonectinmentioning

confidence: 99%

“…The pattern of activity may depend on the type of stimulus (e.g., feeding/exercise vs. erythropoietic stress/hemorrhage) [ 80 ], as when myonectin-deficient mice were administered a high fat diet (HFD), they did not present deviations in morphology [ 70 ]. Better understanding of the link between these two mechanisms may require further studies and the correlation between insulin resistance and iron metabolism may be considered in their design [ 79 ].…”

Section: Myonectinmentioning

confidence: 99%

See 1 more Smart Citation

Review of Novel Potential Insulin Resistance Biomarkers in PCOS Patients—The Debate Is Still Open

Kruszewska

Laudy-Wiaderny²,

Kunicki

2022

IJERPH

View full text Add to dashboard Cite

Research on proteins and peptides that play roles in metabolic regulation, which may be considered potential insulin resistance markers in some medical conditions, such as diabetes mellitus, obesity and polycystic ovarian syndrome (PCOS), has recently gained in interest. PCOS is a common endocrine disorder associated with hyperandrogenemia and failure of ovulation, which is often accompanied by metabolic abnormalities, including obesity, dyslipidemia, hyperinsulinemia, and insulin resistance. In this review, we focus on less commonly known peptides/proteins and investigate their role as potential biomarkers for insulin resistance in females affected by PCOS. We summarize studies comparing the serum fasting concentration of particular agents in PCOS individuals and healthy controls. Based on our analysis, we propose that, in the majority of studies, the levels of nesfastin-1, myonectin, omentin, neudesin were decreased in PCOS patients, while the levels of the other considered agents (e.g., preptin, gremlin-1, neuregulin-4, xenopsin-related peptide, xenin-25, and galectin-3) were increased. However, there also exist studies presenting contrary results; in particular, most data existing for lipocalin-2 are inconsistent. Therefore, further research is required to confirm those hypotheses, as well as to elucidate the involvement of these factors in PCOS-related metabolic complications.

show abstract

Section: Myonectinmentioning

confidence: 99%